Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The IL-7R antagonist Lusvertikimab reduces leukemic burden in xenograft-ALL via antibody-dependent cellular phagocytosis.
Lenk L, Baccelli I, Laqua A, Heymann J, Reimer C, Dietterle A, Winterberg D, Mary C, Corallo F, Taurelle J, Narbeburu E, Neyton SL, Déramé M, Pengam S, Vogiatzi F, Bornhauser B, Bourquin JP, Raffel S, Dovhan V, Schüler T, Escherich G, den Boer ML, Boer JM, Wessels W, Peipp M, Alten J, Antić Ž, Bergmann AK, Schrappe M, Cario G, Brüggemann M, Poirier N, Schewe DM. Lenk L, et al. Among authors: alten j. Blood. 2024 Mar 22:blood.2023021088. doi: 10.1182/blood.2023021088. Online ahead of print. Blood. 2024. PMID: 38518105 Free article.
Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment.
Eckert C, Hagedorn N, Sramkova L, Mann G, Panzer-Grümayer R, Peters C, Bourquin JP, Klingebiel T, Borkhardt A, Cario G, Alten J, Escherich G, Astrahantseff K, Seeger K, Henze G, von Stackelberg A. Eckert C, et al. Among authors: alten j. Leukemia. 2015 Aug;29(8):1648-55. doi: 10.1038/leu.2015.59. Epub 2015 Mar 9. Leukemia. 2015. PMID: 25748682
Molecular characterization of acute lymphoblastic leukemia with high CRLF2 gene expression in childhood.
Schmäh J, Fedders B, Panzer-Grümayer R, Fischer S, Zimmermann M, Dagdan E, Bens S, Schewe D, Moericke A, Alten J, Bleckmann K, Siebert R, Schrappe M, Stanulla M, Cario G. Schmäh J, et al. Among authors: alten j. Pediatr Blood Cancer. 2017 Oct;64(10). doi: 10.1002/pbc.26539. Epub 2017 Apr 1. Pediatr Blood Cancer. 2017. PMID: 28371317 Clinical Trial.
An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts.
Schewe DM, Alsadeq A, Sattler C, Lenk L, Vogiatzi F, Cario G, Vieth S, Valerius T, Rosskopf S, Meyersieck F, Alten J, Schrappe M, Gramatzki M, Peipp M, Kellner C. Schewe DM, et al. Among authors: alten j. Blood. 2017 Sep 28;130(13):1543-1552. doi: 10.1182/blood-2017-01-764316. Epub 2017 Jul 11. Blood. 2017. PMID: 28698205 Free article.
TP53, ETV6 and RUNX1 germline variants in a case series of patients developing secondary neoplasms after treatment for childhood acute lymphoblastic leukemia.
Junk SV, Klein N, Schreek S, Zimmermann M, Möricke A, Bleckmann K, Alten J, Dagdan E, Cario G, Kratz CP, Schrappe M, Stanulla M. Junk SV, et al. Among authors: alten j. Haematologica. 2019 Sep;104(9):e402-e405. doi: 10.3324/haematol.2018.205849. Epub 2019 Jul 9. Haematologica. 2019. PMID: 31289210 Free PMC article. No abstract available.
Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targets.
Hoell JI, Ginzel S, Kuhlen M, Kloetgen A, Gombert M, Fischer U, Hein D, Demir S, Stanulla M, Schrappe M, Zur Stadt U, Bader P, Babor F, Schuster F, Strahm B, Alten J, Moericke A, Escherich G, von Stackelberg A, Thiele R, McHardy AC, Peters C, Bornhauser B, Bourquin JP, Krause S, Enczmann J, Meyer LH, Eckert C, Borkhardt A, Meisel R. Hoell JI, et al. Among authors: alten j. Blood Adv. 2019 Oct 22;3(20):3143-3156. doi: 10.1182/bloodadvances.2019000051. Blood Adv. 2019. PMID: 31648313 Free PMC article.
146 results